bluebird bio Priced, Nasdaq: BLUE
Developing gene therapies for severe genetic and orphan diseases.
Industry: Health Care
First Day Return: +58.3%
BLUE
Developing gene therapies for severe genetic and orphan diseases.
| IPO Data | |
|---|---|
| IPO Date | 06/18/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $101 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 1992 |
| Employees at IPO | 50 |
| Website www.bluebirdbio.com | |
IPO News for bluebird bio
bluebird bio (BLUE) Performance
